No SAE events noted in chronic non-responders whose livers are somewhat compromised. This is compelling and opens the door wide to treat naive patients in Phase Ib/II.
I am quite content with the PR today. Well written and covered all the issues I wanted addressed, especially in clarifying it was a single dose study and advised about the protocol extension. It appears they are close to determining MTD.
News 
Market Data 
Discover 
AI
